Johnson & Johnson announces $5.5-billion settlement of talc lawsuits
The deal must be accepted by 95% of the ovarian cancer claimants in state or federal court before it becomes final
-
-
Moderna, Merck breakthrough could usher in wave of cancer vaccines
Unlike chemotherapy, which kills both healthy and cancerous cells, or immunotherapy, which revs up the immune system, personalized cancer vaccines train the immune system to specifically target mutations found only on a person’s tumor
